ReviewBiological trace element research2026
Copper-Induced Nephropathy: Clinical Characterization of 36 Cases and Comprehensive Literature Review.
Review in Biological trace element research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The etiology of chronic kidney disease (CKD) is complex, with environmental copper exposure emerging as a non-traditional risk factor whose nephrotoxic mechanisms and impacts require in-depth investigation. This study conducted a retrospective analysis of 36 patients with abnormally elevated urinary copper levels, evaluating their clinical manifestations, biochemical indicators, and responses following copper chelation therapy, along with a literature review to explore the relationship between copper levels and renal injury. The results demonstrated a significant correlation between urinary copper content and the severity of renal dysfunction (P < 0.001). After treatment, improvements were observed in renal function (BUA P = 0.046), liver function (ALT P = 0.013), and anemia indicators (HGB P = 0.034). These findings indicate that abnormal urinary copper is a risk factor for kidney injury.
Indexed as
Identifiers
41231370What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.